N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France
Completed
- Conditions
- Allergic Rhinitis Due to House Dust MiteAllergic Asthma Due to Dermatophagoides FarinaeAllergic Asthma Due to Dermatophagoides Pteronyssinus
- Registration Number
- NCT03746860
- Lead Sponsor
- ALK-Abelló A/S
- Brief Summary
Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.
- Detailed Description
Condition:
* persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication
* HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1508
Inclusion Criteria
- At the discretion of the investigator, patient who will be prescribed ACARIZAX® in line with the approved Summary of Product Characteristics (SmPC) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent
Exclusion Criteria
- Patient who did not have 12 months prior inclusion or have an on-going, House Dust Mite (HDM) Allergy Immunotherapy (AIT).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety analysis: Number of patients with at least one Adverse Event 1 year Number of patients with at least one Adverse Events related to ACARIZAX®.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hôpital Arnaud de Villeneuve
🇫🇷Montpellier, France